News|Articles|May 1, 2026

FDA updates in urology: April 2026

Author(s)Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from April 2026.

Welcome to Urology Times’® monthly FDA update! This month’s regulatory activity features several potentially practice-changing developments across the field, including early movement toward a possible testosterone therapy label expansion, high-impact regulatory progress in perioperative bladder cancer therapy, and FDA advisory committee support for capivasertib (Truqap) in PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). Notably, the FDA’s signals around testosterone replacement therapy could meaningfully reshape care in men’s health, while priority review of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in muscle-invasive bladder cancer (MIBC) has the potential to redefine the standard of care if approved.

Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.